Chemotherapy-induced Peripheral Neuropathy and Quality of Life in Breast Cancer Patients

Hye Young Kim; Jeong Hee Kang; Chi Eun Song; Hyun Jo Youn

doi:10.5388/aon.2013.13.4.222

Journal List > Asian Oncol Nurs > v.13(4) > 1081778

Go to TopGo to Top Go to BottomGo to Bottom

TOOLS

Kim, Kang, Song, and Youn: Chemotherapy-induced Peripheral Neuropathy and Quality of Life in Breast Cancer Patients

Original Article

Asian Oncology Nursing 2013; 13(4): 222-230.

Published online: 31 December 2013

DOI: https://doi.org/10.5388/aon.2013.13.4.222

Chemotherapy-induced Peripheral Neuropathy and Quality of Life in Breast Cancer Patients

Hye Young Kim¹, Jeong Hee Kang¹, Chi Eun Song², Hyun Jo Youn³

¹College of Nursing, Chonbuk National University, Jeonju, Korea.

²Department of Hematology, Chonnam National University Hwasun Hospital, Hwasun, Korea.

³Department of Surgery, Chonbuk National University Medical School, Jeonju, Korea.

Address reprint requests to: Kang, Jeong Hee. School of Nursing, Chonbuk National University, 567 Baekje-daero, Deokjin-gu, Jeonju 561-756, Korea. Tel: +82-63-270-3125, Fax: +82-63-270-3127, jeonghee@jbnu.ac.kr

Received 10 November 2013 Accepted 18 December 2013

(open-access):

This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/3.0/) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.

Abstract

Purpose

This study was performed to identify the levels of paclitaxel-containing chemotherapy-induced peripheral neuropathy (CIPN) in relation to quality of life (QOL) in patients with breast cancer.

Methods

A total of 82 breast cancer patients with CIPN participated in this study. Data were collected through self-reported questionnaires containing three instruments by the European Organization for Research and Treatment of Cancer (EORTC), such as QLQ-C30 for health-related QOL, QLQ-BR23 for breast cancer-related QOL, and QLQ-CIPN20 for CIPN. Scores from all three instruments were transformed into 0 to 100 scale. Data were analyzed using SPSS/WIN20 with descriptive statistics and Pearson's correlations.

Results

The mean score for each subscale of health-related QOL was 46.14 for global health status, 62.43 for functional scale, and 31.29 for symptom scale. The mean score for each subscale of breast cancer-related QOL was 56.55 for the functional scale and 42.06 for the symptom scale. Also, the CIPN's mean score on the sensory scale was 30.42, 24.03 on the motor scale, and 22.70 on the autonomic scale. There were significant moderate correlations between QOLs and CIPN (r ranged from -.37 to .65).

Conclusion

There is a need to develop interventions for breast cancer patients to enhance their quality of life and to alleviate chemotherapy-induced peripheral neuropathy.

Keywords: Breast Neoplasms, Peripheral Neuropathies, Quality of Life

Figures and Tables

Table 1

Participants' Characteristics (N=82)

CIPN=Chemotherapy-induced peripheral neuropathy; ECOG PS= Eastern Cooperative Oncology Group Performance Status; AC+P= Doxorubicin/cyclophosphamide sequential paclitaxel; A → T → C= Doxorubicin followed by paclitaxel followed by cyclophosphamide every 2 weekly regimen with filgrastim support; AC → T+T= doxorubicin/cyclophosphamide followed by paclitaxel plus trastuzmab.

Table 2

Participants' Level of CIPN and QOL (N=82)

CIPN=Chemotherapy-induced peripheral neuropathy; QOL=Quality of life.

Table 3

Participants who Reported "Quite a Bit" or "Very Much" on CIPN Items (N=82)

Note. Items are presented after omitting several wordings from the original items.

CIPN=chemotherapy-induced peripheral neuropathy.

Table 4

Mean Differences of CIPN according to Participants' Characteristics (N=82)

CIPN=Chemotherapy-induced peripheral neuropathy; ECOG PS=Eastern Cooperative Oncology Group Performance Status; AC+P=Doxorubicin/cyclophosphamide sequential paclitaxel; A → T → C=Doxorubicin followed by paclitaxel followed by cyclophosphamide every 2 weekly regimen with filgrastim support; AC → T+T=Doxorubicin/cyclophosphamide followed by paclitaxel plus trastuzmab.

Table 5

Correlations between CIPN and QOL (N=82)

CIPN=Chemotherapy-induced peripheral neuropathy; QOL=Quality of life.

References

1. National Cancer Information Center. National cancer statistics. Accessed October 29, 2013. http://www.cancer.go.kr/mbs/cancer/subview.jsp?id=cancer_040102000000.

2. Kirsner RS, Ma F, Fleming LE, Federman DG, Trapido E, Duncan R, et al. Earlier stage at diagnosis and improved survival among Medicare HMO patients with breast cancer. J Womens Health (Larchmt). 2010; 19:1619–1624.

3. Sasane M, Tencer T, French A, Maro T, Beusterien KM. Patient-reported outcomes in chemotherapy-induced peripheral neuropathy: a review. J Support Oncol. 2010; 8(6):15–21.

4. Postma TJ, Aaronson NK, Heimans JJ, Muller MJ, Hildebrand JG, Delattre JY, et al. The development of an EORTC quality of life questionnaire to assess chemotherapy-induced peripheral neuropathy: the QLQ-CIPN20. Eur J Cancer. 2005; 41:1135–1139.

5. Visovsky C, Collins M, Abbott L, Aschenbrenner J, Hart C. Putting evidence into practice: evidence-based interventions for chemotherapy-induced peripheral neuropathy. Clin J Oncol Nurs. 2007; 11(6):901–913.

6. Tofthagen C, McAllister RD, McMillan SC. Peripheral neuropathy in patients with colorectal cancer receiving oxaliplatin. Clin J Oncol Nurs. 2011; 15(2):182–188.

7. Ocean AJ, Vahdat LT. Chemotherapy-induced peripheral neuropathy: pathogenesis and emerging therapies. Support Care Cancer. 2004; 12:619–662.

8. Ferguson T, Wilcken N, Vagg R, Ghersi D, Nowak AK. Taxanes for adjuvant treatment of early breast cancer. Cochrane Database Syst Rev. 2007; Accessed November 1, 2013. http://www.update-software.com/pdf/CD004421.pdf.

9. Shimozuma K, Ohashi Y, Takeuchi A, Aranishi T, Morita S, Kuroi K, et al. Taxane-induced peripheral neuropathy and health-related quality of life in postoperative breast cancer patients undergoing adjuvant chemotherapy: N-SAS BC 02, a randomized clinical trial. Support Care Cancer. 2012; 20(12):3355–3364.

10. Wampler MA, Hamolsky D, Hamel K, Melisko M, Topp KS. Case report: painful peripheral neuropathy following treatment with docetaxel for breast cancer. Clin J Oncol Nurs. 2005; 9(2):189–193.

11. Richardson PG, Briemberg H, Jagannath S, Wen PY, Barlogie B, Berenson J, et al. Frequency, characteristics, and reversibility of peripheral neuropathy during treatment of advanced multiple myeloma with bortezomib. J Clin Oncol. 2006; 24(19):3113–3120.

12. Kim JH, Choi KS, Kim TW, Hong YS. Quality of life in colorectal cancer patients with chemotherapy-induced peripheral neuropathy. J Korean Oncol Nurs. 2011; 11(3):254–262.

13. Clark PG, Cortese-Jimenez G, Cohen E. Effects of reiki, yoga, or meditation on the physical and psychological symptoms of chemotherapy-induced peripheral neuropathy: a randomized pilot study. J Evid Based Complementary Altern Med. 2012; 17(3):161–171.

14. Cavaletti G, Cornblath DR, Merkies ISJ, Postma TJ, Rossi E, Frigeni B, et al. The chemotherapy-induced peripheral neuropathy outcome measures standardization study: from consensus to the first validity and reliability findings. Ann Oncol. 2013; 24(2):454–462.

15. Kim HY, Kang JH, Yoon HJ, Jung SH, So HS, Kim SR. Reliability and validity of the Korean version of the EORTC quality of life questionnaire to assess chemotherapy-induced peripheral neuropathy: the QLQ-CIPN20. In : Poster session presented at the meetings of the 4th Global Breast Cancer Conference; 2013 Oct 10-12; Seoul, Korea.

16. Faul F, Erdfelder E, Buchner A, Lang AG. Statistical power analyses using G*Power 3.1: tests for correlation and regression analyses. Behav Res Methods. 2009; 41:1149–1160.

17. Fayers PM, Aaronson NK, Bjordal K, Groenvold M, Curran D, Bottomley A, et al. The EORTC QLQ-C30 scoring manual. 3rd ed. Brussels: European Organization for Research and Treatment of Cancer;2001.

18. Yun YH, Park YS, Lee ES, Bang SM, Heo DS, Park SY. Validation of the Korean version of the EORTC QLQ-C30. Qual Life Res. 2004; 13:863–868.

19. Yun YH, Bae SH, Kang IO, Shin KH, Lee R, Kwon SI, et al. Cross-cultural application of the Korean version of the European Organization for Research and Treatment of Cancer (EORTC) Breast Cancer Specific Quality of Life Questionnaire (EORTC QLQ-BR23). Support Care Cancer. 2004; 12(6):441–445.

20. Kwak MK, Kim EJ, Lee ER, Kwon IG, Hwan MS. Characteristics and quality of life in patients with chemotherapy-induced peripheral neuropathy. J Korean Oncol Nurs. 2010; 10(2):231–239.

21. Lee J, Ahn MH, Jang YH, Lee EJ, Park JH, Rho J, et al. Toxicity and quality of life of Korean breast cancer patients treated with docetaxel-containing chemotherapy without primary G-CSF prophylaxis. Breast Cancer. 2013; Accessed November 1, 2013. http://link.springer.com/article/10.1007/s12282-013-0442-x#page-1.

22. Merli F, Bertini M, Luminari S, Mozzana R, Berte R, Trottini M, et al. Quality of life assessment in elderly patients with aggressive non-Hodgkin's lymphoma treated with anthracycline-containing regimens. Haematologica. 2004; 89(8):973–978.

23. Kautio A, Haanpaa M, Kautianinen H, Kalso E, Saarto T. Burden of chemotherapy-induced neuropathy: a cross-sectional study. Support Care Cancer. 2011; 19:1991–1996.

24. Wolf SL, Barton DL, Qin R, Wos EJ, Sloan JA, Liu H, et al. The relationship between numbness, tingling, and shooting/burning pain in patients with chemotherapy-induced peripheral neuropathy (CIPN) as measured by the EORTC QLQ-CIPN instrument, N06CA. Support Care Cancer. 2012; 20:625–632.

25. Tofthagen C, Overcash J, Kip K. Falls in persons with chemotherapy-induced peripheral neuropathy. Support Care Cancer. 2012; 20:583–589.

TOOLS

Similar articles